Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

During FDA-declared shortages, pharmacists can legally make compounded versions of brand-name medications. But drugmakers and ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The fight against obstructive sleep apnea (OSA) has taken a monumental leap forward. For the first time, the U.S. Food and ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...

The FDA on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug ...

Tirzepatide was favored over ... are associated with reduced apnea-hypopnea index (AHI), body mass index (BMI), weight, and ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...